Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.45 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.40 |
| ▸ | TSPO | P30536 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 3/20 | 0.39 |
| ▸ | TOP1 | P11387 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13316087 | 0.89 | METAP1 (0.49) | METAP1ABCG2NR1I3GRM2HDAC6 | |
| SCHEMBL4090406 | 0.87 | METAP1 (0.49) | METAP1ABCG2NR1I3TSPOATM | |
| SCHEMBL11917056 | 0.85 | DHFR (0.39) | ABCG2NR1I3TSPOHDAC6HTT | |
| SCHEMBL25463096 | 0.80 | MEN1 (0.57) | METAP1ABCG2HTTNPC1RAB9A | |
| SCHEMBL17275213 | 0.80 | METAP1 (0.57) | METAP1ABCG2HTTNPC1RAB9A | |
| SCHEMBL18518213 | 0.80 | MEN1 (0.47) | HDAC6NPC1RAB9AMAPK1TOP1 | |
| SCHEMBL16404333 | 0.79 | METAP1 (0.61) | METAP1ABCG2HTTNPC1RAB9A | |
| SCHEMBL384799 | 0.79 | METAP1 (0.61) | METAP1ABCG2HTTATMPDE5A | |
| SCHEMBL31009730 | 0.79 | ABCG2 (0.58) | METAP1ABCG2MAPK1PDE5AMEN1 | |
| SCHEMBL4840414 | 0.79 | ABCG2 (0.58) | METAP1ABCG2MAPK1PDE5AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125139-A1 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | BANKSTON DONALD | 2010-05-20 | — | — | US | claimed |
| EP-1370553-B1 | RHO-KINASE INHIBITORS | BAYER AG (US) | 2006-05-10 | — | — | EP | claimed |
| EP-1542992-A2 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | Bayer Corporation (US) | 2005-06-22 | — | — | EP | claimed |
| WO-2004029045-A2 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | claimed |
| EP-1370553-A2 | RHO-KINASE INHIBITORS | Bayer Corporation (US) | 2003-12-17 | — | — | EP | claimed |
| US-20030220357-A1 | Process for preparing quinazoline Rho-kinase inhibitiors and intermediates thereof | BAYER HEALTHCARE LLC | 2003-11-27 | — | — | US | claimed |
| WO-2002076976-A2 | RHO-KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-03 | — | — | WO | claimed |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | disclosed |
| US-20100125139-A1 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | BANKSTON DONALD | 2010-05-20 | — | — | US | disclosed |
| US-7645878-B2 | Reacting an aniline derivative with an acylchloride to form an intermeidate, cyclizing the intermediate, replacing hydroxy group with a leaving group (chloride), racting the product with an amino-heterocyclic compound | BAYER HEALTHCARE LLC (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1953152-A1 | Process for preparing quinazoline RHO-kinase inhibitors and intermediates thereof | Bayer Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20060142313-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2006-06-29 | — | — | US | disclosed |
| EP-1370553-B1 | RHO-KINASE INHIBITORS | BAYER AG (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1542992-A2 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | Bayer Corporation (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004029045-A2 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20030220357-A1 | Process for preparing quinazoline Rho-kinase inhibitiors and intermediates thereof | BAYER HEALTHCARE LLC | 2003-11-27 | — | — | US | disclosed |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | BAYER CORPORATION | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142313-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | METAP1 1724/4885ABCG2 3107/4885NR1I3 2534/4885 |
| US-20030220357-A1 | Process for preparing quinazoline Rho-kinase inhibitiors and intermediates thereof | ROCK1, ROCK2, RHOT2 | METAP1 1794/4885ABCG2 1704/4885NR1I3 3588/4885 |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | CIT, PDE3A, PDE2A | METAP1 2652/4885ABCG2 1193/4885NR1I3 2680/4885 |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | METAP1 1724/4885ABCG2 3107/4885NR1I3 2534/4885 |
| US-20100125139-A1 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | ROCK1, ROCK2, CIT | METAP1 1905/4885ABCG2 1652/4885NR1I3 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.